Zai Lab Limited (FRA:1ZL)

Market Cap	2.10B -27.4%
Revenue (ttm)	391.91M +15.3%
Net Income	-149.50M
EPS	-1.36
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7
Open	18.60
Previous Close	18.40
Day's Range	18.60 - 18.60
52-Week Range	13.20 - 38.20
Beta	n/a
RSI	54.63
Earnings Date	May 7, 2026

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 1,784
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1ZL

Financial Performance

In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.

Financial numbers in USD